I’ve been on chemo (cabazitaxel + carboplatin) since Jan 2022 and also on Zometa and Lupron. PSA went from 1.3 in Jan 2023 to 11.7 this month. CT and Bone scans show bone mets somewhat stable but with activity, all bone no soft tissue. PET PSMA earlier this year did not show enough tracer activity to indicate Lutetium-177 (available at UC Davis, CA with long lead time).
So we are in the process of changing treatment to Radium-223. When asked if I should stay on Xtandi, both my MOs said it’s ok to continue and pretty much left it up to me as there’s no indication it’s affective since PSA is rising.
Any thoughts on staying on Xtandi in which case treatment would be:
Radium-223, Lupron, Xtandi, Zometa.
I appreciate your input,
Blessings to you.
Written by
MechD
To view profiles and participate in discussions please or .
You can use both Ra223 and Xtandi, but it is important to get Zometa during that time. This study states: "Bone health agents should be administered and bone health should be closely monitored following treatment with radium-223 and enzalutamide."
My husband just did what you are doing - Ra223, Lupron, Xtandi, Xgeva instead of Zometa (bone strength). Even though your PSA is rising, the thought expressed is that ADT is still providing some benefit, putting on the breaks for some of the cancer cells.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.